OBJECTIVES::  To evaluate the budget impact of including secukinumab for the treatment of moderate-to-severe plaque psoriasis patients from the perspective of the Brazilian private healthcare system over five years. METHODS::  Excel-based model was developed to estimate investment required for inclusion of secukinumab, as an additional biologic alternative by comparing two scenarios: "without-secukinumab" versus "with-secukinumab". Number of patients eligible for biologic therapy was calculated considering: (1)hypothetical population of 1,000,000; (2)prevalence of psoriasis patients about 1%; (3)85% of these are plaque psoriasis patients; (4)20% presenting moderate-to-severe disease; (5)50% are eligible for systemic therapy; (6)40% of these are eligible for biologic therapy; (7)annual discontinuation rate of biologic therapy: around 10%; and (8)from the second year on, an annual incidence of 59.9/100,000 was considered to calculate new psoriasis patients entrance. 25% and 20% of market share for each biologic was considered in the “without-secukinumab” and “with-secukinumab” scenarios, respectively. Drug annual costs were based on the respective ex-factory prices and the recommended dosages. Infliximab cost was based on an average body weight of 70kg. RESULTS:: The number of patients eligible for treatment with biologic agents was estimated to be around 340 in the first year with an incidence of 20. The annual costs of maintenance therapy with biologic agents were estimated to be: BRL46,614 (ustekinumab 45mg); BRL74,778 (secukinumab); BRL87,748 (etanercept); BRL93,227 (ustekinumab 90mg); BRL96,533 (adalimumab); BRL96,607 (infliximab 100mg). The total budget impact was negative around: -BRL4 million in 5 years (average: -BRL838K per year) [1BRL=0,32USD; 30/Jan/2017]. CONCLUSIONS:: The annual maintenance therapy cost with secukinumab is the second lowest cost among all biologic agents. The introduction of secukinumab could generate savings from the perspective of private healthcare system according to this model. To evaluate the budget impact of including secukinumab for the treatment of moderate-to-severe plaque psoriasis patients from the perspective of the Brazilian private healthcare system over five years